Skip to main content
. Author manuscript; available in PMC: 2020 Dec 15.
Published in final edited form as: J Acquir Immune Defic Syndr. 2019 Dec 15;82(5):503–513. doi: 10.1097/QAI.0000000000002185

Figure 1: High levels of IL-32 in plasma from cART-treated HIV+ individuals.

Figure 1:

Shown are (A) plasma levels of total IL-32 in HIVneg (n=107), HIV+ viremic individuals (n=46), and HIV+ virologically-suppressed on cART individuals (n=379). Numbers on the graph refer to the median levels of IL-32 in plasma of each group expressed as pg/ml. (B) correlation between total IL-32 levels and Log10 viral load (VL) (left panel), CD4/CD8 ratios (middle panel) in viremic individuals (n=46) and CD4/CD8 ratios in cART-treated individuals (right panel). Data were analyzed by the non-parametric Kruskal-Wallis and Dunn’s sub-test for multiple comparisons in A. Spearman correlation test was used to assess the significance of correlations between IL-32 and HIV VL or CD4/CD8 ratio in B. NS, non-significant (p>0.05).